Across TCGA pan-cancer cohorts, INO80C Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated INO80C data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher INO80C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated INO80C expression acts as an unfavorable survival marker.
LUAD, LIHC, and SARC are the cancer types where INO80C Mutation most reproducibly stratifies survival.